Do you know what this company does? what they sell? how many FDA approved test kits, how many employees they have, how many new hospitals they added as customers? Do you know how many FDA approvals are expected this quarter? Do you know how many new trials they are starting this year? This isnt a broken or busted company, just the vicitim of scummy funders who screwed them over like many other small up and comers.
Since I know you dont know those answers here you go.
125 employee's
100 new hospitals/customers added
2 FDA approvals this quarter
4-5 new trials starting this year
$$$$$$
Great Basin Announces 186 Customers to End 2015
8:00 AM ET 1/5/16
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced it added 46 new customers in the fourth quarter of 2015. As of December 31st, the company had secured 186 U.S. customers, compared to 84 customers reported at the end of December 2014, representing an increase of 121 percent year over year. Further, Great Basin's Group B Streptococcus (GBS) test--which was commercially launched on June 1, 2015--has now been adopted by or is scheduled to be evaluated by 80 sites, which represents 43 percent of the Company's customer base.
Additionally, the Company announced updates to the 2016 product roadmap and status for previously announced products and FDA submissions. Newly announced additional products and timing for 2016 include:
-- Pertussis/Parapertussis Test - clinical trial expected to commence in first half of 2016
-- CT/NG Test - clinical trial expected to commence early second half of 2016
The status of previously announced products in development is as follows:
-- SA Nasal Screen Test - clinical trial expected to commence first half of 2016
-- Stool Bacterial Pathogens Panel - clinical trial expected to commence in first half of 2016
-- Candida Blood Infections Panel - clinical trial expected to commence in the second half of 2016
In the second half of 2015, Great Basin submitted its Staph ID/R Blood Culture Panel and Shiga Toxin Direct Test to the U.S. Food & Drug Administration (FDA) for 510(k) clearance following the successful completion of clinical trials. The Company anticipates response from the FDA for both submissions in the first quarter of 2016. Based on initial FDA review of the submissions, the Company anticipates response for the Shiga Toxin Direct Test prior to response for the Staph ID/R Blood Culture Panel due to the complexity of the submission for a panel diagnostic assay.
Ryan Ashton, co-founder and Chief Executive Officer of Great Basin said, "Great Basin is pleased to meet our guidance for customer acquisition in 2015, and we're excited to announce the additions to our product roadmap in 2016."
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company's website at www.gbscience.com.
News 
Market Data 
Discover 
